Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix Q1 Revenues Jump, Net Loss Narrows

NEW YORK, April 21 (GenomeWeb News) - Affymetrix today reported an increase in revenues and a dramatic narrowing of its net loss compared to the year ago quarter.


The market leader in the mass production of microarrays, Affymetrix reported total revenues of $79 million for the quarter that ended March 31, compared to total revenues of $67 million for the year-ago quarter.


The company had a net loss of $1.9 million for the quarter, compared to a loss of $12.7 million for its first quarter of 2003. The loss included a charge of $8.1 million associated with the company's redemption of a set of 4.75 and 5.0 percent convertible subordinated notes.


The company reported research and development expenses of $17 million, compared to $16 million for the same quarter in 2003.

The Scan

Back as Director

A court has reinstated Nicole Boivin as director of the Max Planck Institute for the Science of Human History, Science reports.

Research, But Implementation?

Francis Collins reflects on his years as the director of the US National Institutes of Health with NPR.

For the False Negatives

The Guardian writes that the UK Health Security Agency is considering legal action against the lab that reported thousands of false negative COVID-19 test results.

Genome Biology Papers Present Epigenetics Benchmarking Resource, Genomic Architecture Maps of Peanuts, More

In Genome Biology this week: DNA methylation data for seven reference cell lines, three-dimensional genome architecture maps of peanut lines, and more.